RxDoctor Payments Data

Parisa Farhi, MD

Glaucoma Specialist · Blacksburg, VANPI 1376672717

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Alcon at 51.5% of the total. 2025 is the largest year on record at $45, 2.4 times the $19 reported in 2023.

$88in general payments, 2019–2025

Across 4 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$45
  • Thea Pharma Inc.$24
  • Rayner Intraocular Lenses Limited$19

What the payments were for

  • Food & beverage$88100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few glaucoma specialist providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$905,341
Medicare patients
1,936
Services billed
9,862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine50$57,555
RhopressaNetarsudil Mesylate101$47,670
VyzultaLatanoprostene Bunod63$27,295
LumiganBimatoprost52$26,235
XiidraLifitegrast18$21,441
Latanoprost2,724$20,463
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol98$19,489
Prednisolone Acetate350$16,096
Cyclosporine30$16,002
Brimonidine Tartrate776$11,040
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat595$10,846
Timolol MaleateTimolol Maleate/Pf27$9,795
Alphagan PBrimonidine Tartrate23$9,446
MoxifloxacinMoxifloxacin Hcl343$9,212
CombiganBrimonidine Tartrate/Timolol23$7,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$45$7,35129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Blacksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →